Floatz logo

Recombinant Vaccinia-Cea/Tricom Vaccine

Recurrent Rectal Cancer

National Cancer Institute (NCI)vaccinePhase 1Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
89/ 100

Competitive context

70 Active assets in the Recurrent Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sun Yat-sen University
Phase 4BBB
FLUOROURACILUM
Seoul National University Hospital
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Capecitabine
Tao Zhang
Phase 3BB

View all 50 →

Same molecule, other indications

Recombinant Vaccinia-Cea/Tricom Vaccine is also rated in:

breast cancerDormant
CC
Indicative ·
41 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
40 / 100
View asset →
Adult Solid NeoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →